SEARCH

SEARCH BY CITATION

Literature Cited

  • 1
    Shevach EM. The effects of cyclosporin A on the immune system. Annu Rev Immunol 1985; 3: 397423.
  • 2
    Granelli-Piperno A,Nolan P,Inaba K,Steinman RM. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. J Exp Med 1990; 172: 18691872.
  • 3
    Granelli-Piperno A. Lymphokine gene expression in vivo is inhibited by cyclosporin A. J Exp Med 1990; 171: 533544.
  • 4
    Flechner SM,Kobashigawa J,Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 115.
  • 5
    Amodio P,Biancardi A,Montagnese S,Angeli P,Iannizzi P,Cillo U,D'Amico D,Gatta A. Neurological complications after orthotopic liver transplantation. Dig Liver Dis 2007; 39: 740747.
  • 6
    Moien-Afshari F,McManus BM,Laher I. Immunosuppression and transplant vascular disease: Benefits and adverse effects. Pharmacol Ther 2003; 100: 141156.
  • 7
    Neuhaus P,Klupp J,Langrehr JM. mTOR inhibitors: An overview. Liver Transpl 2001; 7: 473484.
  • 8
    Schuler W,Sedrani R,Cottens S,Haberlin B,Schulz M,Schuurman HJ,Zenke G,Zerwes HG,Schreier MH. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 3642.
  • 9
    Schuurman HJ,Cottens S,Fuchs S,Joergensen J,Meerloo T,Sedrani R,Tanner M,Zenke G,Schuler W. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporin. Transplantation 1997; 64: 3235.
  • 10
    Pascual J,Ioannis NB,Josep MC. Everolimus (Certican) in renal transplantation: A review of clinical trial data, current usage, and future directions. Transpl Rev 2006; 20: 118
  • 11
    Vítko S,Margreiter R,Weimar W,Dantal J,Kuypers D,Winkler M,Øyen O,Viljoen HG,Filiptsev P,Sadek S,Li Y,Cretin N,Budde K;RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 25212530.
  • 12
    Eisen HJ,Tuzcu EM,Dorent R,Kobashigawa J,Mancini D,Valantine-von Kaeppler HA,Starling RC,Sørensen K,Hummel M,Lind JM,Abeywickrama KH,Bernhardt P;RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847858.
  • 13
    Wood KJ,Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199210.
  • 14
    Battaglia M,Stabilini A,Migliavacca B,Horejs-Hoeck J,Kaupper T,Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 83388347.
  • 15
    Coenen JJ,Koenen HJ,van Rijssen E,Hilbrands LB,Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107: 10181023.
  • 16
    Zeiser R,Leveson-Gower DB,Zambricki EA,Kambham N,Beilhack A,Loh J,Hou JZ,Negrin RS. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111: 453462.
  • 17
    Basu S,Golovina T,Mikheeva T,June CH,Riley JL. Cutting edge: Foxp3-mediated induction of PIM2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180: 57945798.
  • 18
    Battaglia M,Stabilini A,Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 47434748.
  • 19
    Game DS,Hernandez-Fuentes MP,Lechler RI. Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am J Transplant 2005; 5: 454464.
  • 20
    Masetti M,Montalti R,Rompianesi G,Codeluppi M,Gerring R,Romano A,Begliomini B,Di Benedetto F,Gerunda GE. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10: 22522262.
  • 21
    Barbieri D,Abbracchio MP,Salvioli S,Monti D,Cossarizza A,Ceruti S,Brambilla R,Cattabeni F,Jacobson KA,Franceschi C. Apoptosis by 2-chloro-2′-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int 1998; 32: 493504.
  • 22
    Cossarizza A,Pinti M,Moretti L,Bricalli D,Bianchi R,Troiano L,Fernandez MG,Balli F,Brambilla P,Mussini C,Viganò A. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. J Infect Dis 2002; 185: 299305.
  • 23
    Foli A,Benvenuto F,Piccinini G,Bareggi A,Cossarizza A,Lisziewicz J,Lori F. Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 2001; 15: 16871694.
  • 24
    Franceschi C,Monti D,Scarfi MR,Zeni O,Temperani P,Emilia G,Sansoni P,Lioi MB,Troiano L,Agnesini C,Salvioli S,Cossarizza A. Genomic instability and aging. Studies in centenarians (successful aging) and in patients with Down's syndrome (accelerated aging). Ann N Y Acad Sci 1992; 663: 416.
  • 25
    Nemes E,Bertoncelli L,Lugli E,Pinti M,Nasi M,Manzini L,Manzini S,Prati F,Borghi V,Cossarizza A,Mussini C. Cytotoxic granule release dominates gag-specificCD4+ T-cell response in different phases of HIV infection. AIDS 2010; 24: 947957.
  • 26
    Girolomoni G,Zambruno G,Manfredini R,Zacchi V,Ferrari S,Cossarizza A,Giannetti A. Expression of B7 costimulatory molecule in cultured human epidermal Langerhans cells is regulated at the mRNA level. J Invest Dermatol 1994; 103: 5459.
  • 27
    Cossarizza A,Ferraresi R,Troiano L,Roat E,Gibellini L,Bertoncelli L,Nasi M,Pinti M. Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry. Nat Protoc 2009; 4: 17901797.
  • 28
    Troiano L,Ferraresi R,Lugli E,Nemes E,Roat E,Nasi M,Pinti M,Cossarizza A. Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc 2007; 2: 27192727.
  • 29
    Nemes E,Lugli E,Bertoncelli L,Nasi M,Pinti M,Manzini S,Prati F,Manzini L,Del Giovane C,D'Amico R,Cossarizza A,Mussini C. CD4+ T-cell differentiation, regulatory T cells and gag-specific T lymphocytes are unaffected by CD4-guided treatment interruption and therapy resumption. AIDS 2011; 25: 14431453.
  • 30
    Roederer M,Nozzi JL,Nason MC. SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry Part A 2011; 79A: 167174.
  • 31
    Ormandy LA,Hillemann T,Wedemeyer H,Manns MP,Greten TF,Korangy Fl. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 24572464.
  • 32
    Curiel TJ,Coukos G,Zou L,Alvarez X,Cheng P,Mottram P,Evdemon-Hogan M,Conejo-Garcia JR,Zhang L,Burow M,Zhu Y,Wei S,Kryczek I,Daniel B,Gordon A,Myers L,Lackner A,Disis ML,Knutson KL,Chen L,Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942949.
  • 33
    Ichihara F,Koji K,Takahashi A,Kawaida H,Sugai H,Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9: 44044408.
  • 34
    Manigold T,Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: Facts and controversies. Lancet Infect Dis 2007; 7: 804813.
  • 35
    Boyman O,Ramsey C,Kim DM,Sprent J,Surh CD. IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J Immunol 2008; 180: 72657275.
  • 36
    Li W,Carper K,Zheng XX,Kuhr CS,Reyes JD,Liang Y,Perkins DL,Thomson AW,Perkins JD. The role of Foxp3+ regulatory T cells in liver transplant tolerance. Transplant Proc 2006; 38: 32053206.
  • 37
    Fourtounas C,Dousdampanis P,Sakellaraki P,Rodi M,Georgakopoulos T,Vlachojannis JG,Mouzaki A. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients. Am J Nephrol 2010; 32: 19.
  • 38
    Oo YH,Weston CJ,Lalor PF,Curbishley SM,Withers DR,Reynolds GM,Shetty S,Harki J,Shaw JC,Eksteen B,Hubscher SG,Walker LS,Adams DH. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol 2010; 184: 28862898.
  • 39
    Cossarizza A. T cell repertoire in HIV infection: Facts and perspectives. AIDS 1997; 11: 10751088.
  • 40
    Cossarizza A,Poccia F,Agrati C,D'Offizi G,Bugarini R,Pinti M,Borghi V,Mussini C,Esposito R,Ippolito G,Narciso P. Highly active antiretroviral therapy restores CD4+ Vβ T cell repertoire in patients with primary, acute HIV infection but not in treatment-naive HIV+ patients with chronic infection. J AIDS 2004; 35: 213222.
  • 41
    Masetti M,Rompianesi G,Montalti R,Romano A,Spaggiari M,Ballarin R,Guerrini GP,Gerunda GE. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: Preliminary results. Transplant Proc 2008; 40: 19471949.
  • 42
    Yoon K. Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: A new therapeutic option. Ann N Y Acad Sci 2009; 1173: 752756.